Martín LC, Sánchez FPL, Cañizo C, González SJM, Herreros J, Prosper F

Language: Spanish
References: 10
Page: 462-467
PDF size: 104.42 Kb.

ABSTRACT

Heart failure is a broad term that encompasses the end stages of the most the heart diseases. Despite of the last advances in the treatment of this disease during the last years, the mortality keeps on being very important, even higher than the most malignant tumor´s one. The evidence that cardiomyocytes are able to multiply, has made possible new ways to treat the heart failure, and in this sense first investigations of cellular therapy apply to myocardium have begun recently. Myocardium cellular therapy has created expectation, and not only several animal but human models have been published with the propose of study if the mother cell implant in the necrotic myocardium achieves ventricular function improvement, avoids heart failure and could be useful in heart failure treatment. Human clinical trials have used mother cells from differents sources, such as red bone marrow, embryonic cells, skeletal muscle, which have been implant by intracoronary, transendocardial or transmyocardial way in patients who had suffered a previous myocardial infarct. An improvement in the global heart function, motility of the necrotic segment as well as the myocardial area recovery that previosly was unviable has been observed in all of them. Nevertheless, there is a long way to cover before we could include this therapy in the clinical practice.

REFERENCES

1. Beltrami AP, Urbanek K, Jastura J, Yan SM, Bussani R, et al: Evidence that human cardiac myocites divide after myocardial infarction. N Eng J Med 2001; 344: 1750-7.

2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schartz RE, et al: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9.

3. Orlic D, Kajstura J, Chimenti S, Limana F, Jakouniuk I, Quaini F, et al: Mobilized bone marrow cells repair the infracted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344-9.

4. Laflamme MA, Myerson D, Saffitz JE, Murry CE: Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human heart. Circ Res 2002; 90: 634-40.

5. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al: Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100: II247-56.

6. Shake JG, Baumgartner WA, Senechal G, Meyers J, Remond JM, et al: Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Sug 2002; 73: 1919-25.

7. Kessler PD, Byrne BJ: Myoblast cell grafting into heart muscle: cellular biology and potential applications. Annu Rev Physiol 1999; 61: 219-42.

8. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, et al: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-33.

9. Herreros J, Prosper F, Gavira JJ, García-Velloso MJ, Barba J, Sánchez PL, Cañizo C, Rabago G, Martí-Climent JM, Hernández M, López-Holgado N, González-Santos JM, Martín-Luengo C, Alegria E: Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 2003; 24: 2012-2020.

10. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, et al: Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1078-83.